A trial looking at intensity modulated arc therapy for neuroblastoma (IMAT)

This trial compared the standard dose of radiotherapy with a higher dose for people with neuroblastoma. With the standard, older, type of radiotherapy it is difficult to treat the neuroblastoma adequately. While at the same time avoiding too much radiation to important organs.

This study aimed to find out if a new type of radiotherapy called intensity modulated arc therapy would allow the increased dose to be given safely to patients. This is when compared with the older type of radiotherapy.

This trial was for children older than 18 months as well as adults.

It was open for people to join between 2017 and 2020. The team published the results in 2024.